Peptidyl 3-substituted 1-hydroxyureas as isosteric analogues of succinylhydroxamate MMP inhibitors

被引:16
作者
Campestre, Cristina [1 ]
Tortorella, Paolo [2 ]
Agamennone, Mariangela [1 ]
Preziuso, Serena [1 ]
Biasone, Alessandro [1 ]
Nuti, Elisa [3 ]
Rossello, Amando [3 ]
Gallina, Carlo [1 ]
机构
[1] Univ G DAnnunzio, Dipartimento Sci Farmaco, I-66013 Chieti, Italy
[2] Univ Bari, Dipartimento Farmacochim, I-70125 Bari, Italy
[3] Univ Pisa, Dipartimento Sci Farmaceut, I-56126 Pisa, Italy
关键词
MMP inhibition; peptidyl N-hydroxyureas; succinyl hydroxamates;
D O I
10.1016/j.ejmech.2007.07.002
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
To evaluate N-hydroxyurea as zinc binding group in the design of MMP inhibitors, two peptidyl 1-hydroxyureas were prepared by N-hydroxycarbamoylation of the diastereomeric dipeptides H-Leu-Phe-NHMe and H-D-Leu-Phe-NHMe. Peptidyl 1-hydroxyureas were more potent than the parent peptides, but dramatically weaker (4-5 orders of magnitude) than the isosteric (R)-succinylhydroxamate analogue, which displays IC(50) in the range of nM vs MMP-1, -3, -7 and sub-nM vs MMP-2, -8, and -9. The peptidyl 1-hydroxyurea la attained an IC50 of 20 mu M vs MMP-9, and substantially approaches inhibition of known N-hydroxyureas based on aminoacids or peptides against other zinc metalloenzymes and non-peptidic N-hydroxyureas against MMPs. Strong preference of the O-N1-C = O unit for the antiperiplanar amide bond conformation seems to be the major limit for more effective zinc chelation. Methylation of a peptidyl 1-hydroxyurea at N3, to promote the synperiplanar O-N1-C = O conformation required for zinc chelation and improve affinity, resulted in release of a methylimidazolidine-2,4-dione through an undesired intramolecular reaction reminiscent of the Edman peptide degradation. (C) 2007 Elsevier Masson SAS. All rights reserved.
引用
收藏
页码:1008 / 1014
页数:7
相关论文
共 43 条
[1]  
Abbenante Giovanni, 2005, Med Chem, V1, P71, DOI 10.2174/1573406053402569
[2]  
[Anonymous], SOFTMAX PRO 4 7 1 MO
[3]   Kinetics and mechanism of base-catalysed degradations of substituted aryl-N-hydroxycarbamates, their N-methyl and N-phenyl analogues [J].
Beier, P ;
Mindl, J ;
Sterba, V ;
Hanusek, J .
ORGANIC & BIOMOLECULAR CHEMISTRY, 2004, 2 (04) :562-569
[4]   Recent non-hydroxamate matrix metalloproteinase inhibitors [J].
Breuer, E ;
Frant, J ;
Reich, R .
EXPERT OPINION ON THERAPEUTIC PATENTS, 2005, 15 (03) :253-269
[5]   N-hydroxyurea as zinc binding group in matrix metalloproteinase inhibition:: Mode of binding in a complex with MMP-8 [J].
Campestre, C ;
Agamennone, M ;
Tortorella, P ;
Preziuso, S ;
Biasone, A ;
Gavuzzo, E ;
Pochetti, G ;
Mazza, F ;
Hiller, O ;
Tschesche, H ;
Consalvi, V ;
Gallina, C .
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2006, 16 (01) :20-24
[6]  
CAMPION C, 1990, Patent No. 9005719
[7]   N-(Hydroxyaminocarbonyl)phenylalanine:: A novel class of inhibitor for carboxypeptidase A [J].
Chung, SJ ;
Kim, DH .
BIOORGANIC & MEDICINAL CHEMISTRY, 2001, 9 (01) :185-189
[8]   Cancer therapy - Matrix metalloproteinase inhibitors and cancer: Trials and tribulations [J].
Coussens, LM ;
Fingleton, B ;
Matrisian, LM .
SCIENCE, 2002, 295 (5564) :2387-2392
[9]   Future challenges facing the development of specific active-site-directed synthetic inhibitors of MMPs [J].
Cuniasse, P ;
Devel, L ;
Makaritis, A ;
Beau, F ;
Georgiadis, D ;
Matziari, A ;
Yiotakis, A ;
Dive, V .
BIOCHIMIE, 2005, 87 (3-4) :393-402
[10]   ASYMMETRIC DIELS-ALDER CYCLOADDITIONS WITH C2-SYMMETRICAL CHIRAL CARBAMOYLNITROSO DIENOPHILES [J].
DEFOIN, A ;
BROUILLARDPOICHET, A ;
STREITH, J .
HELVETICA CHIMICA ACTA, 1991, 74 (01) :103-109